Three Different Ways Researchers Are Trying to Support Mitochondria

Mitochondrial decline shows up in nearly every discussion of aging biology, which is exactly why it's attracted research from several different mechanistic angles rather than a single approach. Three compounds illustrate just how differently "support the mitochondria" can be interpreted.

MOTS-c is unusual in that it's encoded by the mitochondrial genome itself, rather than nuclear DNA — a mitochondria-derived peptide that appears to function as an exercise-responsive signal. Research has linked it to activation of AMPK, the same central metabolic switch that both exercise and metformin engage, and muscle tissue appears to release more of it during physical exertion. Its mechanism is signaling, not structural repair — it's telling cells to shift metabolic behavior, closer to how a hormone works.

SS-31, also known as elamipretide, works at the structural level instead. It binds cardiolipin, the lipid that forms the folded inner mitochondrial membrane, and helps stabilize that structure so the electron transport chain can keep producing energy efficiently while reducing the leakage of reactive oxygen species. Of the three compounds discussed here, SS-31 is by far the most clinically advanced — it has real human trial data behind it and, as of September 2025, holds the first FDA approval ever granted to a mitochondria-targeted peptide, specifically for Barth syndrome.

NAD+ takes a different angle entirely: fuel supply. NAD+ is a coenzyme central to the entire cellular energy production system and to activating sirtuins, proteins linked to metabolic regulation and cellular stress resistance. Levels decline steadily with age, and precursor supplementation has been shown reliably to raise NAD+ levels back up — though, notably, the link between restored NAD+ levels and meaningful health or longevity benefit in humans is considerably less settled than the biomarker change itself.

Looked at together, these three compounds sit at genuinely different points on the evidence spectrum — from early mechanistic research to a real approved therapy — and that spread is a useful reminder that "mitochondrial support" isn't one claim, it's a category covering very different levels of certainty.

Why this matters for tracking: mitochondrial function is reflected across multiple measurable domains — metabolic bloodwork, exercise recovery, resting energy expenditure. Rather than evaluating any single compound in isolation, tracking these markers together over time gives a far clearer picture of whether your own mitochondrial health is trending in the direction you want.